Invitation to Martin Marietta’s Capital Markets Day on September 3, 2025
Globenewswire· 2025-08-27 20:15
RALEIGH, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Martin Marietta Materials, Inc. (NYSE: MLM) (Martin Marietta or the Company), a leading national supplier of aggregates and heavy building materials, invites investors and analysts to the live broadcast of Martin Marietta’s Capital Markets Day on Wednesday, September 3, 2025, beginning at 9:00 a.m. Eastern Time. Ward Nye, Chair, President and Chief Executive Officer, joined by other members of the Company’s leadership team, will discuss Martin Marietta’s stra ...
Four Leaf Acquisition Corporation Announces Receipt of Nasdaq Delisting Determinations
Globenewswire· 2025-08-27 20:15
Core Points - Four Leaf Acquisition Corporation received a notice from Nasdaq regarding its failure to file the Quarterly Report on Form 10-Q for the year ended June 30, 2025, which serves as a basis for potential delisting [1] - The Company has appealed the delisting determination and was granted an extension [1] - On August 27, 2025, the Company filed its Form 10-Q [2] Company Overview - Four Leaf Acquisition Corporation is a blank check company incorporated in Delaware, aiming to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination [3] - The Company is focused on identifying target companies in the Internet of Things (IoT) market [3] - Leadership includes Bala Padmakumar as Chairman and Interim CEO, Coco Kou as CFO, and Robert de Neve as Chief Strategy Officer [3]
CooperCompanies Announces Third Quarter 2025 Results
Globenewswire· 2025-08-27 20:15
SAN RAMON, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2025. Revenue increased 6% year-over-year to $1,060.3 million. CooperVision (CVI) revenue up 6% to $718.4 million, and CooperSurgical (CSI) revenue up 4% to $341.9 million.GAAP diluted earnings per share (EPS) of $0.49, down $0.03 or 6% from last year's third quarter.Non-GAAP diluted EPS of $1.10, up $0.14 o ...
Aardvark Therapeutics to Present at Upcoming Investor Conferences in September
Globenewswire· 2025-08-27 20:10
SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, announced that it will present at the following conferences during September: Cantor Fitzgerald Global Healthcare Conference 2025 in New YorkPresentation: Wednesday, September 3 at 11:30 a.m. ET Morgan Stanley 23rd Annual Global He ...
Olaplex Holdings, Inc. Announces Participation in the Barclays 18th Annual Global Consumer Staples Conference on September 2nd
Globenewswire· 2025-08-27 20:05
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (“OLAPLEX”), today announced its participation in the Barclays 18th Annual Global Consumer Staples Conference in Boston, MA. Amanda Baldwin, Chief Executive Officer, and Catherine Dunleavy, Chief Operating Officer & Chief Financial Officer, will present on Tuesday, September 2, 2025 at 3:45pm ET and hold meetings with investors throughout the day. The audio portion of the fireside chat will be available on the Company’s Investor Relations we ...
MDB Capital Holdings Provides Second Quarter 2025 Update
Globenewswire· 2025-08-27 20:05
Management to Host Conference Call Today at 4:30 p.m. ETAddison, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading “Big Idea” companies, today provides an operational update for the quarter ended June 30, 2025, and subsequent developments. Second Quarter 2025 and Subsequent Operational Highlights Launched private offering for Paulex Bio, a company developing a transformational oral medication designed to e ...
Oxford to Release Second Quarter Fiscal 2025 Results on September 10, 2025
Globenewswire· 2025-08-27 20:05
ATLANTA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE: OXM) today announced that it plans to release its second quarter fiscal 2025 financial results after the market close on Wednesday, September 10, 2025. Following the news release, the company will also hold a conference call starting at 4:30 p.m. ET, hosted by Thomas C. Chubb lll, Chairman, Chief Executive Officer, and President, and K. Scott Grassmyer, Executive Vice President, Chief Financial Officer, and Chief Operating Officer, to ...
Andrew Ross Joins Symbotic’s Board of Directors
Globenewswire· 2025-08-27 20:05
Motion & Control Industry Veteran Brings Deep Knowledge of High-Performance Teams and a Proven Track Record of Success in Public Company OperationsWILMINGTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, today announced the election of Andrew (“Andy”) Ross to its Board of Directors, effective August 26, 2025. Mr. Ross currently serves as President and Chief Operating Officer of Parker-Hannifin Corporation (NYSE: PH), ...
Adaptive Biotechnologies to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Globenewswire· 2025-08-27 20:05
SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Wednesday, September 10th at 10:05 a.m ...
Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program
Globenewswire· 2025-08-27 20:05
MINNEAPOLIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S. Food and Drug Administration (“FDA”) agreed to accept its New Drug Application (“NDA”) for gedatolisib in HR+/HER2- advanced breast cancer (“ABC”) for review under the Real-Time Oncology Review (“RTOR”) program, which facilitates earlier submission of topline efficacy and safety results, prior to the submission o ...